Malignant Pleural Effusion Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Roche Holdings AG, Bristol Myers Squibb, Novartis, Merck

The Malignant Pleural Effusion Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Malignant Pleural Effusion Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malignant Pleural Effusion Market.

Some of the key takeaways from the Malignant Pleural Effusion Pipeline Report:

• Companies across the globe are diligently working toward developing novel Malignant Pleural Effusion treatment therapies with a considerable amount of success over the years. 
• Malignant Pleural Effusion companies working in the treatment market are LIPAC Oncology, Clover Biopharmaceuticals, Wuhan YZY Biopharma Co., Ltd., RS Oncology, Simcere Pharmaceutical Group, and others, are developing therapies for the Malignant Pleural Effusion treatment 

• Emerging Malignant Pleural Effusion therapies in the different phases of clinical trials are- LEIPC-1007, SCB 313, M 701, RSO-021, Endostar, and others are expected to have a significant impact on the Malignant Pleural Effusion market in the coming years.   
• In March 2023, Positive results from the Phase II/III CCTG IND.227/KEYNOTE-483 trial of Keytruda in combination with chemotherapy as first-line therapy for patients with advanced malignant pleural mesothelioma have been released by Merck and the Canadian Cancer Trials Group (CCTG).
• In May 2021, In order to treat malignant pleural effusions, Simcere Pharmaceutical started a study with the following title: "A Randomised, Controlled, Double-blind, Multi-center Phase III Registration Clinical Study of Combined Cisplatin Versus Placebo Combined With IntracavitaryCisplatin Injection."

Malignant Pleural Effusion Overview

A large buildup of exudate in the pleural space combined with the presence of cancerous cells or tumour tissue is known as malignant pleural effusion (MPE). MPE is a serious medical disorder that can cause restricted physical activity, pain, and difficulty breathing.

Get a Free Sample PDF Report to know more about Malignant Pleural Effusion Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/malignant-pleural-effusion-pipeline-insight

Emerging Malignant Pleural Effusion Drugs Under Different Phases of Clinical Development Include:

• LEIPC-1007: LIPAC Oncology
• SCB 313: Clover Biopharmaceuticals R
• M 701: Wuhan YZY Biopharma Co., Ltd.
• RSO-021: RS Oncology
• LEITP-1009: LIPAC Oncology
• SCB-313: Clover Biopharmaceutical
• Endostar: Simcere Pharmaceutical Group

Route of Administration

Malignant Pleural Effusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Malignant Pleural Effusion Pipeline Therapeutics Assessment

• Malignant Pleural Effusion Assessment by Product Type
• Malignant Pleural Effusion By Stage and Product Type
• Malignant Pleural Effusion Assessment by Route of Administration
• Malignant Pleural Effusion By Stage and Route of Administration
• Malignant Pleural Effusion Assessment by Molecule Type
• Malignant Pleural Effusion by Stage and Molecule Type

DelveInsight's Malignant Pleural Effusion Report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Malignant Pleural Effusion product details are provided in the report. Download the Malignant Pleural Effusion pipeline report to learn more about the emerging Malignant Pleural Effusion therapies

Some of the key companies in the Malignant Pleural Effusion Therapeutics Market include:

Key companies developing therapies for Malignant Pleural Effusion are - Roche Holdings AG, Bristol Myers Squibb, Novartis International AG, Merck & Co., Inc., AstraZeneca, Eli Lilly and Company, Pfizer Inc., Boehringer Ingelheim International GmbH, Johnson & Johnson, Genentech, Inc., Celgene Corporation, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, AbbVie Inc., Amgen Inc., and others.

Malignant Pleural Effusion Pipeline Analysis:

The Malignant Pleural Effusion pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Effusion with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Effusion Treatment.
• Malignant Pleural Effusion key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Malignant Pleural Effusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Effusion market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Malignant Pleural Effusion drugs and therapies

Malignant Pleural Effusion Pipeline Market Drivers

• Increase in prevalence of Malignant Pleural Effusion, significant progress in the management of pleural effusions are some of the important factors that are fueling the Malignant Pleural Effusion Market.

Malignant Pleural Effusion Pipeline Market Barriers

• However, complications associated with the treatment, high cost of the treatment and other factors are creating obstacles in the Malignant Pleural Effusion Market growth.

Scope of Malignant Pleural Effusion Pipeline Drug Insight    

• Coverage: Global
• Key Malignant Pleural Effusion Companies: LIPAC Oncology, Clover Biopharmaceuticals, Wuhan YZY Biopharma Co., Ltd., RS Oncology, Simcere Pharmaceutical Group, and others
• Key Malignant Pleural Effusion Therapies: LEIPC-1007, SCB 313, M 701, RSO-021, Endostar, and others
• Malignant Pleural Effusion Therapeutic Assessment: Malignant Pleural Effusion current marketed and Malignant Pleural Effusion emerging therapies
• Malignant Pleural Effusion Market Dynamics: Malignant Pleural Effusion market drivers and Malignant Pleural Effusion market barriers 

Request for Sample PDF Report for Malignant Pleural Effusion Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services